RT Book, Section
A1 Papadakis, Maxine A.
A1 McPhee, Stephen J.
A1 Rabow, Michael W.
A1 McQuaid, Kenneth R.
SR Print(0)
ID 1193123451
T1 Blood Disorders Year in Review
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193123451
RD 2024/09/14
AB For  patients  with  multiagent  refractory  disease,  CAR  T-cell  therapy  targeting  the  early  plasma  cell  antigen  BCMA  has  shown  response  rates  exceeding  70%  and  median  duration  of  response  of  over  11  months.